Arch Biopartners Inc.
OTC: ACHFF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard Gabriel Muruve
- Employees
- 6
- Headquarters
- Toronto, Canada
- IPO year
- 2002
- Market cap
- $50.1M
- Website
- https://www.archbiopartners.com
Loading ACHFF…
Loading profile data…Frequently asked questions about ACHFF
What does Arch Biopartners Inc. (ACHFF) do?
Arch Biopartners Inc. is a biotechnology company focused on developing innovative technologies with significant medical and commercial potential. Their primary endeavor involves advancing Metablok, a lead drug candidate designed to treat or prevent dipeptidase-1 (DPEP-1) mediated inflammation in critical organs like the lungs, liver, and kidneys...
Where does ACHFF trade?
Arch Biopartners Inc. (ACHFF) trades on the Other OTC.
What sector is ACHFF in?
Arch Biopartners Inc. (ACHFF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Arch Biopartners Inc.?
Richard Gabriel Muruve is the chief executive officer of Arch Biopartners Inc. (ACHFF).
Where is Arch Biopartners Inc. headquartered?
Arch Biopartners Inc. is headquartered in Canada.
Does ACHFF pay a dividend?
Arch Biopartners Inc. (ACHFF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ACHFF go public?
Arch Biopartners Inc. (ACHFF) completed its initial public offering in 2002.